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ABSTRACT 
Ulcerated primary melanomas are associated with an inflammatory tumor micro-
environment. We hypothesised that systemic pro-inflammatory states and anti-inflammatory 
medications are also associated with a diagnosis of ulcerated melanoma. In a cross-sectional 
study of 787 patients with newly-diagnosed clinical stage IB or II melanoma, we estimated 
odds ratios (ORs) for the association of pro-inflammatory factors (high body mass index 
(BMI), diabetes, cardiovascular disease, hypertension and smoking) or use of anti-
inflammatory medications (statins, aspirin, corticosteroids and non-steroidal anti-
inflammatory drugs), with ulcerated primary melanoma using regression models and 
subgroup analyses to control for melanoma thickness and mitotic rate. Based on information 
from 194 patients with ulcerated and 593 patients with non-ulcerated primary melanomas, 
regular statin users had lower likelihood of a diagnosis of ulcerated primary melanoma (OR 
0.67, 95% CI 0.45-0.99) and this association remained after adjusting for age, sex, thickness 
and mitosis. When analysis was limited to melanomas that were ≤2mm thick and had ≤2 
mitoses/mm2 (40 ulcerated; 289 without ulceration), patients with diabetes had significantly 
raised odds of diagnosis of ulcerated melanoma (OR 2.90, 95% CI 1.07-7.90), adjusted for 
age, sex, BMI and statin use. These findings support our hypotheses that statin use is 
inversely associated, and diabetes is positively associated, with ulcerated melanoma.  
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INTRODUCTION  
 Ulceration of a primary cutaneous melanoma signifies a poorer prognosis than a non-
ulcerated melanoma of the same thickness and is integral to clinical staging of the 
disease (Balch et al., 2009). The histopathologic features of tumor thickness, ulceration and 
mitotic activity are considered the hallmarks of rapidly growing melanomas (Balch et al., 
2009, Thompson et al., 2011), hence the presence of ulceration likely reflects a highly 
proliferative phenotype. Not all thick or highly mitotic lesions are ulcerated however (Balch 
et al., 2009), and this suggests that processes other than cell proliferation may influence the 
development of ulceration (Balch et al., 2009, Gogas et al., 2009, Spatz et al., 2010, 
Thompson et al., 2011).  
 Neither a patient’s age or sex, nor the melanoma’s anatomic location or level of 
pigmentation appear to be associated with ulceration (Balch et al., 1980, Newton-Bishop et 
al., 2014). However, evidence suggests inflammation in the tumor microenvironment is 
linked to ulceration (Jewell et al., 2015, Storr et al., 2012, Winnepenninckx et al., 2006) as 
shown by the greater numbers of macrophages, increased microvessel density and higher 
expression of genes encoding inflammatory and wound-healing factors in ulcerated 
lesions (Jewell et al., 2015, Storr et al., 2012, Winnepenninckx et al., 2006). Although 
targeted immune activation is used therapeutically in melanoma to induce long-term survival 
in metastatic disease, there is overwhelming evidence that ‘smouldering’ inflammation in the 
tumor microenvironment suppresses antitumor activity and aids angiogenesis, cancer cell 
proliferation, survival and metastasis (Mantovani et al., 2008, Melnikova and Bar-Eli, 2009). 
‘Smouldering’ inflammation has been described as chronic, often subclinical, inflammation 
involving macrophages, granulocytes and chemical mediators and causing inhibition of T-
cell-dependent antitumor activities (Balkwill et al., 2005). Thus while it is clear that a 
component of unfavourable tumor inflammation is intrinsically driven by oncogenic changes, 
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it remains largely unknown if factors associated with systemic pro-inflammatory states, may 
also enhance tumor inflammation and ulceration.  
 Systemic factors known to cause pro-inflammatory states include obesity, diabetes, 
hypertension, cardiovascular disease and smoking (van Kruijsdijk et al., 2009). The chronic 
inflammatory activation observed in obese people is thought to contribute to their higher risk 
of developing other types of cancer including breast, endometrial, colorectal or liver 
cancer (Mazzarella, 2015, Sutherland et al., 2004) as well as chronic diseases such as 
hypertension, diabetes and cardiovascular disease (2010, Herder et al., 2016, Wang et al., 
2013, Wang et al., 2016). A prevalent inflammatory state is also observed in smokers as 
evidenced by quantifiable increases in circulating inflammatory markers (Bakhru and 
Erlinger, 2005) implicated in the pathogenesis of cardiovascular disease. 
Medications with anti-inflammatory properties, such as statins (Ferri and Corsini, 
2014), nonsteroidal anti-inflammatory drugs (NSAIDs) (Green, 2001) and 
corticosteroids (Recio and Fuentes, 2012) are commonly used to reduce the burden of 
systemic inflammation in patients with imminent or established cardiovascular disease or 
other chronic conditions and their anti-inflammatory properties may also be relevant to the 
pathogenesis of inflamed and ulcerated melanomas. 
 The only published study investigating the relationship between ulceration and 
systemic inflammatory factors (Newton-Bishop et al., 2014) reported that ulceration was 
associated with diabetes, smoking, lower vitamin D levels and higher BMI at diagnosis. 
Although this was a cohort study, all clinical stages including very late stage melanomas 
were included, so that the observed associations with ulceration could not be distinguished 
from associations with late diagnosis. Thus new evidence is required to clarify if systemic 
pro-inflammatory factors and medications with anti-inflammatory properties are indeed 
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associated with promotion or inhibition of melanoma-genesis respectively and the presence 
or not of ulceration. If potentially modifiable factors were shown to be associated with 
melanoma ulceration this would assist in targeted prevention and enable clinicians to advise 
patients in an informed manner. We therefore explored whether the systemic inflammation 
linked to smoking, obesity, hypertension, diabetes and cardiovascular disease or alternatively, 
if the anti-inflammatory properties of medications such as statins, nonsteroidal anti-
inflammatory drugs and corticosteroids, are associated with the diagnosis of an ulcerated 
rather than a non-ulcerated primary melanoma independent of other associated 
histopathological features of melanoma.  
 
RESULTS 
Patient characteristics 
 Of the 1,254 invited patients, 825 (66%) consented to take part. A further 38 patients 
were found to be ineligible after consent, leaving 787 study participants (mean age at 
diagnosis, 62 years; 57% male). Of the 787, 194 (25%) melanomas were reported as showing 
ulceration on histopathological examination. Participants with ulcerated melanoma were 
older (56% >65 years), more likely to be male, more likely to have outdoor occupations, and 
they had thicker (>2mm) rather than thinner (≤2mm) melanomas and higher numbers of 
mitoses (>6/mm2) than those with non-ulcerated primary melanomas (all p<0.05) (Table 1).  
Pro- and anti-inflammatory factors and ulceration  
  After adjustment for age and sex, regular statin users were significantly less likely to 
be diagnosed with an ulcerated melanoma compared to nonusers (OR 0.67, 95% CI 0.45-
0.99) and this inverse association remained strong and significant after further adjustment for 
thickness and mitosis (OR 0.64, 95% CI 0.42-0.98) (Table 2). Similarly, regular aspirin, 
NSAIDs and corticosteroid use all tended towards inverse associations with ulceration (Table 
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2). Patients using at least one of either statins, aspirin or NSAIDs regularly, were less likely 
to be diagnosed with an ulcerated melanoma when adjusted for age, sex, thickness and 
mitotic rate (OR 0.68, 95% CI 0.46-1.00) (Table 2). Pro-inflammatory factors (obesity, 
smoking, hypertension, diabetes and cardiovascular disease) were not associated with 
ulceration in this analysis.  
 We used three model selection techniques to determine which patient features, 
histopathological and/or inflammatory factors were associated with melanoma ulceration. 
These model selection approaches were considered due do their diverse criteria and their 
different abilities to produce a set of efficient, parsimonious statistical predictors. Using an 
exhaustive model selection approach, thickness, mitosis, regression, aspirin use and weekend 
sun exposure best predicted ulceration status (best AIC: 665). This model produced an area 
under the ROC curve of 0.74 (95% CI 0.70-0.79), indicating good discriminative ability. 
When utilising a lasso model selection technique, age, sex, thickness, mitotic rate, statin use 
and BMI were selected as best fit, with an AIC value of 604 and AUC ROC curve=0.75 (95 
% CI 0.70-0.79). The same parameters were obtained using a stepwise regression approach, 
with the addition of corticosteroid use AUC ROC curve = 0.74 (95 % CI 0.70-0.79). (Table 
S1).  
Subgroup analysis  
 Amongst the subgroup of melanomas with relatively low proliferation (≤2mm thick 
and ≤2/mm2 mitotic rate), 40 (12%) were ulcerated and 298 not ulcerated. After adjustment 
for age and sex, diabetes increased the odds of ulcerated melanoma (OR 2.89, 95% CI 1.26-
6.60) and this association remained when adjusted further for BMI and statin use (OR 2.90, 
95% CI 1.07-7.90) (Table 3). Overweight or obesity, hypertension and heart disease were 
positively and use of statins, aspirin or NSAIDs were inversely associated with ulceration, 
but none significantly (Table 3).  The magnitude of the association between regular statin use 
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and ulcerated melanoma in the subgroup analysis (Table 3) was very similar to that obtained 
in the overall analysis, although again it was not significant.  
 
DISCUSSION 
 There is clear evidence that the tumor microenvironments of most melanomas are 
inflamed, but ulcerated melanomas are associated with especially high levels of tumor 
inflammation (Jewell et al., 2015, Melnikova and Bar-Eli, 2009, Winnepenninckx et al., 
2006) with high density of macrophages, microvessels (Jewell et al., 2015, Storr et al., 2012) 
and enhanced expression of the genes encoding inflammatory and wound-healing 
factors (Jewell et al., 2015, Winnepenninckx et al., 2006). In this cross-sectional study of 
localised primary melanomas at high risk of recurrence, we explored whether factors that are 
believed to modify the level of systemic inflammation, may also be associated with 
melanoma ulceration status. Our primary finding suggests that statin users have a 
substantially decreased likelihood of being diagnosed with an ulcerated melanoma compared 
with non-users after adjusting for age, sex, thickness and mitotic rate. Other medications with 
anti-inflammatory properties (aspirin, NSAIDs and corticosteroids) also demonstrated strong 
inverse relationships with ulcerated melanomas.  
 As other characteristics of fast-growing tumors, namely increased thickness and 
mitotic rate, are highly associated with tumor ulceration, we removed their influence in a 
subgroup analysis of patients who had melanomas without these features. Within this 
subgroup, diabetics were more than twice as likely to be diagnosed with ulcerated than non-
ulcerated melanoma. While we did not observe any other significant association with 
ulceration in this smaller subgroup, it is notable that, free of confounding by thickness >2mm 
and mitotic rate >2/mm2, positive and inverse associations were seen as hypothesised with all 
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pro-inflammatory and anti-inflammatory factors respectively that could be assessed, and the 
strong inverse association between ulcerated melanoma and statins remained, albeit no longer 
significant in the smaller sample.  
  While statins are traditionally used as cholesterol-lowering medications, they are 
becoming increasingly recognised for their anti-cancer effects, regulating tumor proliferation, 
apoptosis, angiogenesis and metastasis that occur via inhibition of metabolic products of the 
3-hydroxy-3-methylglutaryl coenzyme A reductase reaction, including the inhibition of Rho 
GTPases and Rho dependant signalling pathways  (Hindler et al., 2006, Sarrabayrouse et al., 
2017). Early epidemiological studies suggested statins may prevent melanoma 
development (Downs et al., 1998), yet more recent studies do not support this (Bonovas et al., 
2010, Curiel-Lewandrowski et al., 2011, Jagtap et al., 2012).  There is however growing 
evidence that statins may reduce melanoma mortality, particularly in males (Livingstone et 
al., 2014). In our cohort, statin use decreased the likelihood of being diagnosed with an 
ulcerated versus non-ulcerated melanoma. It is possible that statins modify inflammatory 
mechanisms involved in tumor ulceration, and that this reduction may, at least in part, 
account for the reduced melanoma progression and metastasis observed in regular statin 
users (Dulak and Józkowicz, 2005).  
 We observed that the other medications with anti-inflammatory properties that we 
assessed were also negatively associated with ulcerated melanomas when adjusted for 
thickness and mitotic rate though non-significantly. We therefore suggest that the 
chemoprotective effects of NSAIDs, aspirin and corticosteroids on tumor ulceration and 
inflammation also warrant further exploration in larger prospective studies. In addition, the 
dosage and duration of medication use may be important determinants of potential 
chemoprotective effects and should be considered in prospective studies. (Cuzick et al., 2009, 
Rothwell et al., 2010).  
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 In the subgroup of melanomas with relatively low proliferation, diabetic patients were 
more commonly diagnosed with an ulcerated versus non-ulcerated melanoma and this 
association remained after adjusting for potential confounding factors. We deduce that we did 
not observe this association in the overall analysis due to residual confounding by thickness 
or mitotic rate. This positive association is consistent with results from a recent cohort study 
also showing a positive association between diabetes and ulceration in univariate 
analysis (Newton-Bishop et al., 2014). Diabetes is a known pro-inflammatory state, as 
evidenced by low-grade elevation of circulating markers such as C- reactive protein, sialic 
acid and pro-inflammatory cytokines. Diabetics have higher incidence rates of primary cancer 
(liver, pancreas, endometrium, colon, breast and bladder cancer) and micro- and macro-
vascular pathology, and there is general consensus that the pathogenesis of these diseases in 
diabetics is linked to activation of inflammatory pathways (Giovannucci et al., 2010). It is 
also possible that the higher likelihood of melanoma ulceration in diabetics, as observed in 
the subgroup analysis, may be mediated by diabetes-induced inflammation. Regular 
surveillance of diabetic patients at high-risk of melanoma would be clinically indicated, if 
diabetes were confirmed to increase risk of melanoma ulceration. 
 Strengths of this study include the epidemiological evidence regarding a possible 
association between ulcerated melanomas and systemic inflammatory factors that accounts 
for the potential confounding by melanoma thickness and mitotic rate. Our results are based 
on a large cohort of localised primary melanomas of >1mm thickness, with detailed clinical 
and histological data obtained from pathological reports. The major limitation of our study is 
its cross-sectional design. Also our self-reported medication measures may have been subject 
to recall error, and missing data decreased the statistical power of some analyses. We did not 
perform histological evaluation of cases to confirm ulceration status, however inter-observer 
agreement in reporting melanoma features is high in Australia  (Murali et al., 2009).  
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 In summary, we have demonstrated that regular statin users have reduced likelihood 
of a diagnosis of ulcerated melanoma. Amongst patients with melanomas of relatively low 
proliferation, it was seen that diabetics also have a higher probability of an ulcerated versus 
non-ulcerated melanoma. Evidence from larger prospective studies is required to confirm 
whether these associations between ulcerated lesions and statins and diabetes are causal 
relationships. Further investigation into the chemoprotective role of other specific anti-
inflammatory medications is also warranted.   
 
MATERIALS AND METHODS 
Study population  
Participants were recruited prospectively between October 2010 and October 2014, 
from various specialist public Queensland hospital clinics, and private practices of 
collaborating surgeons. Patients were invited to participate by their treating doctor with 
written, informed consent (or by study personnel with doctors’ permission) if they met the 
following inclusion criteria: histologically-confirmed new diagnosis of stage IB or II 
cutaneous melanoma, aged over 16 years, and capacity to complete the study questionnaire. 
Eligible patients were also ascertained through the main private pathology services in 
Queensland, when pathologists included a standard note about the study on all relevant 
histopathology reports. The note informed treating doctors about the study and asked them to 
notify the pathology company if their patients should not be contacted. Patients for whom no 
objection was obtained within 2 weeks were sent information about the study with request for 
permission to release their details to study personnel who then invited the patients concerned 
to take part with written, informed patient consent. The study was approved by the Human 
Research Ethics Committees of the Metro South Hospital and Health Service and the QIMR 
Berghofer Medical Research Institute.   
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Data collection 
All participants completed a standard self-administered questionnaire at baseline 
giving personal details, including sex, age, height, weight, highest level of education (less 
than year 12, technical college or diploma, university), smoking history (current, ex-smoker, 
never smoked), total lifetime number of painful sunburns (0-1, 2-5, >6) and skin type (always 
burn/never tan, burn then tan, tan only). Participants indicated amount of time spent outdoors 
on an average weekend (<5hours, 5-8hours) and whether their main occupations were 
indoors, both indoors and outdoors, or outdoors.  Patients were asked to indicate frequency 
(never, less than 50%, more than 50%, all the time) of use of sun protection measures 
(including hats, sunscreen, long-sleeves, and sunglasses).  
Positive histories of previous melanoma were confirmed by obtaining histology 
reports. Information about melanoma in a first degree relative (yes, no) was obtained and 
whether participants had been diagnosed previously with diabetes, cardiovascular disease or 
hypertension (yes, no). As well, use (yes, no), dosage (mg), frequency (daily, weekly etc.) 
and starting and stopping dates of statins, NSAIDs and corticosteroids in the preceding 5 
years were recorded at baseline. History of medication use was updated (with addition of 
history of aspirin use) by questionnaire for all active participants in April 2016. For patients 
who were lost to follow-up in April 2016, information on aspirin use was obtained from GP 
referral letters to specialist melanoma units regarding their index melanoma.  
Histological details of all primary melanomas were extracted from histopathology 
reports including thickness (mm) and presence of ulceration (yes, no) or mitosis (per mm2 or 
per high power field) or regression (yes, no) as well as site of melanoma (head or neck, trunk, 
upper limb, lower limb). If the histopathology report did not specify ulceration was present, 
ulceration was classified as absent. 
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Statistical analysis 
 Based on their responses to the baseline questionnaire or to the follow-up medication 
survey, or on information provided in clinical referral letters, patients were categorised as 
regular users of statins, aspirin or other NSAIDs, or corticosteroids if they had taken 3+ 
tablets per week, every week, for any continuous 3-month period in the 2 years prior to their 
diagnosis. If regular medication commencement or cessation date was unknown or missing 
for a patient, these were categorised as ‘missing’.  
Body mass index (BMI) was calculated as weight (kg) / height (m)2 and categorised 
as underweight/normal <25, overweight 25-30 or obese >30. We created a summary variable 
for use of sun-protection measures (sunscreen, protective clothing, hats and sunglasses). 
Subjects’ adherence to sun-protection measures for >50% of time outdoors were categorised 
as nil, at least 1, 2-4 measures used. A combined anti-inflammatory variable was created 
based on regular use of either statins, aspirin or NSAIDs. Mitotic rate was categorised as <2, 
2-6, >6 mm2  prior to analysis based on the observed distribution of mitotic rate (when mitotic 
rate was reported per hpf (n=23), it was first converted to rate per mm2). When mitotic rate 
was only qualitatively described in the pathology report (n=21) it was coded as missing.  
Pearson’s chi-squared tests were used to examine associations between tumor 
ulceration status and patient and tumor characteristics. Multivariable logistic regression 
analyses were conducted to assess the associations between inflammatory factors and 
presence of ulceration, controlling firstly for age and sex, and then for age, sex, melanoma 
thickness and mitotic rate.  
Interactions between clinical, histological and inflammatory parameters with 
ulceration status were explored in exhaustive best-subset selection, lasso  (Tibshirani, 2011) 
and stepwise regression model selection techniques. Variables with p<0.9 on univariate 
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analysis were included in model building analyses and p<0.1 was used as the selection 
criterion for the stepwise regression approach. Under the exhaustive selection method, 
models were ranked based on observed Akaike information criterion (AIC) values. Our lasso 
criteria chose the regularization parameter λ = ρi where ρ = 0.8 and i is the ith step in the 
selection process as implemented in SAS 9.4. We used the area under the Receiver Operating 
Characteristic curve (AUC ROC) to assess discriminative ability of the selected models. 
Due to the strong association between ulceration, mitosis and tumor thickness 
confirmed in model selection analyses, we also performed a subgroup analysis, nominated a 
priori, in patients whose melanomas were ≤2mm thick and ≤2/mm2 mitotic rate in order to 
entirely eliminate confounding by thick or highly mitotic melanomas. For the purposes of this 
paper, we refer to this subgroup as melanomas with relatively low proliferation. Due to the 
small numbers of exposed cases, smoking and corticosteroid use were not included in the 
subgroup analyses, and use of either aspirin or NSAIDs or statins was analysed as a 
combined variable. To identify associations of pro-and anti-inflammatory factors and 
ulceration in those with relatively low proliferation melanomas, we conducted multivariable 
regression analyses adjusting for age and sex alone and for age, sex, BMI, diabetes and statin 
use. All statistical analyses were performed using SAS software version 9.4. 
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Table 1. Baseline characteristics of 787 patients with primary melanoma in relation to 
presence of melanoma ulceration   
 Total  
(n=787)  
N (%) 
Ulcerated 
(n=194)  
N (%) 
Not Ulcerated 
(n=593)  
N (%) 
Chi-square  
P-value  
Patient factors 
Age (years)   
    ≥65 
    < 65 
 
377 (48) 
410 (52) 
 
108 (56) 
86 (44) 
 
271 (45) 
322 (55) 
 
0.02 
Sex 
    Male  
    Female 
 
447 (57) 
340 (43) 
 
125 (64) 
69 (36) 
 
322 (54) 
271 (46) 
 
0.01 
Education  
    High school or less   
    Trade/ Diploma  
    University                  
 
403 (51) 
228 (29) 
155 (20) 
 
110 (57) 
50 (26) 
34 (17) 
 
293 (50) 
178 (30) 
121 (20) 
 
0.23 
 
Occupation  
    Indoors   
    Both  
    Outdoors  
 
274 (35) 
381 (48) 
132 (17) 
 
62 (32) 
86 (44) 
46 (24) 
 
212 (35) 
295 (50) 
86 (15) 
 
0.01 
Weekend sun  
    <4 hours 
    5-8 hours   
 
564 (73) 
209 (27) 
 
130 (70) 
57 (30) 
 
434 (74) 
152 (26) 
 
0.44 
Lifetime sunburns 
    Never/ Once  
    2-5  
    >5 
 
87 (11) 
264 (33) 
435 (56) 
 
26 (13) 
68 (25) 
100 (52) 
 
61 (10) 
196 (33) 
335 (57) 
 
0.34 
Sun protection  
    Never  
    Use 1 >50% 
    Use 2-4 >50% 
 
125 (16) 
427 (54) 
235 (30) 
 
27 (14) 
108 (56) 
59 (30) 
 
98 (16) 
319 (54) 
176 (30) 
 
0.67 
Skin type  
    Always burn  
    Burn then tan  
    Tan only  
 
307 (39) 
398 (51) 
78 (10) 
 
70 (36) 
99 (51) 
25 (13) 
 
237 (40) 
299 (51) 
53 (13) 
 
0.25 
Previous melanoma  
    No   
    Yes   
 
623 (79) 
164 (21) 
 
160 (83) 
34 (17) 
 
463 (78) 
130 (22) 
 
0.19 
Family history  
    No  
    Yes  
 
565 (73) 
213 (27) 
 
140 (73) 
51 (27) 
 
425 (73) 
163 (27) 
 
0.88 
Primary melanoma factors 
Thickness (mm)  
    <1 
    1.01-2.00 
    2.01-4.00 
    >4 
 
206 (26) 
334 (43) 
176 (22) 
69 (8) 
 
21 (11) 
75 (39) 
58 (30) 
40 (21) 
 
185 (31) 
259 (44) 
118 (20) 
29 (5) 
 
<0.0001 
Mitosis (no./mm2) 
    <2 
    2-6 
    >6 
 
286 (37) 
328 (43) 
152 (20) 
  
35 (18) 
76 (40) 
81 (42) 
  
251 (44) 
252 (44) 
71 (12) 
 
<0.0001 
Regression  
    No  
    Yes  
 
497 (63) 
288 (37) 
  
132 (68) 
62 (32) 
  
365 (62) 
226 (38) 
  
0.12 
Body site (location)  
    Head/neck  
    Trunk 
    Upper limb  
    Lower limb  
 
167 (21) 
273 (35) 
165 (21) 
182 (23) 
 
44 (23) 
73 (38) 
32 (16) 
45 (23) 
 
123 (21) 
200 (34) 
133 (22) 
137 (23) 
 
0.35 
For some variables, the summed total is less than the total number of patients because of missing values 
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Table 2. Factors associated with pro- and anti-inflammatory effects in relation to melanoma 
ulceration  
 Total  
(n=787) 
N (%) 
Ulceration 
(n=194)  
N (%) 
No 
Ulceration 
(n=593)  
N (%) 
Multivariate1 
OR (95% CI) 
Multivariate2  
OR (95% CI) 
Pro-inflammatory factors 
BMI 
    <25 
    25-29.9 
    ≥30 
 
210 (29) 
298 (41) 
221 (30) 
 
49 (27) 
83 (46) 
48 (27) 
 
161 (29) 
215 (39) 
173 (32) 
 
1.00 
1.19 (0.78-1.77) 
0.89 (0.56-1.40) 
 
1.00 
1.27 (0.80-2.01) 
0.93 (0.56-1.53) 
Smoking  
    Nonsmoker  
    Current  
    Ex-smoker 
 
396 (53) 
59 (8) 
295 (39) 
 
97 (52) 
15 (8) 
74 (40) 
 
297 (53) 
44 (8) 
220 (39) 
 
1.00 
1.11 (0.59-2.13) 
0.99 (0.69-1.41) 
 
1.00 
1.09 (0.55-2.16) 
0.97 (0.66-1.43) 
Hypertension  
    No  
    Yes 
 
220 (67) 
109 (33) 
 
22 (45) 
18 (55) 
 
198 (31) 
22 (69) 
 
1.00 
0.94 (0.65-1.35) 
 
1.00 
0.85 (0.57-1.27) 
Diabetes 
    No  
    Yes 
 
686 (87) 
101 (13) 
 
166 (86) 
28 (14) 
 
517 (88) 
73 (12) 
 
1.00 
1.06 (0.65-1.71) 
 
1.00 
1.11 (0.66- 1.88) 
Heart disease 
    No  
    Yes      
 
684 (87) 
103 (13) 
 
162 (84) 
32 (16) 
 
520 (70) 
70 (12) 
 
1.00 
1.23 (0.76-1.98) 
 
1.00 
1.29 (0.77- 2.18) 
Anti-inflammatory factors 
Statins  
    No  
    Yes  
 
556 (72) 
218 (28) 
 
143 (75) 
48 (25) 
 
410 (71) 
170 (29) 
 
1.00 
0.67 (0.45-0.99) 
 
1.00  
0.64 (0.42-0.98) 
Aspirin  
    No 
    Yes  
 
560 (78) 
155 (22) 
 
137 (79) 
36 (21) 
 
420 (78) 
119 (22) 
 
1.00 
0.76 (0.49-1.18) 
 
1.00  
0.78 (0.48-1.26)  
NSAIDS  
    No  
    Yes 
 
658 (97) 
21 (3) 
 
156 (97) 
5 (3) 
 
500 (97) 
16 (3) 
 
1.00 
1.04 (0.37-2.91) 
 
1.00 
0.79 (0.26-2.43) 
Anti-inflammatory3 
    No 
    Yes 
 
489 (62) 
298 (38) 
 
125 (64) 
69 (36) 
 
361 (61) 
229 (39) 
 
1.00 
0.72 (0.50-1.03) 
 
1.00 
0.68 (0.46-1.00) 
Corticosteroid 
    No  
    Yes 
 
723 (93) 
55 (7) 
 
182 (94) 
11 (6) 
 
540 (93) 
43 (7) 
 
1.00 
0.69 (0.35-1.38) 
 
1.00 
0.55 (0.25- 1.19) 
 
1- Adjusted for age and sex  
2- Adjusted for age, sex, thickness and mitosis 
3- Regular use of either statins, aspirin or NSAIDS 
For some variables, the summed total is less than the total number of patients because of missing values 
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Table 3. Pro-inflammatory factors associated with melanoma ulceration in a population 
subgroup (mitosis ≤2/mm2 and thickness ≤2mm) 
 
 
Ulceration  
40 (12)  
N (%)  
No ulceration 
289 (88)  
N (%) 
OR (95% CI)1 OR (95% CI)2 
Pro-inflammatory factors 
BMI 
    <25 
    25-29.9 
    ≥30 
 
6 (16) 
19 (50) 
13 (34) 
 
86 (31) 
106 (39) 
81 (30) 
 
1.00 
2.60 (0.99-6.84) 
2.32 (0.84-6.41) 
 
1.00 
2.63 (0.99-6.96) 
2.06 (0.70-6.02) 
Hypertension 
    No 
    Yes 
 
22 (55) 
18 (45) 
 
198 (68) 
91 (32) 
 
1.00 
1.91 (0.93-3.92) 
 
1.00 
1.91 (0.84-4.32) 
Diabetes 
    No  
    Yes  
 
30 (75) 
10 (25) 
 
258 (89) 
31 (11) 
  
1.00  
2.89 (1.26-6.60) 
 
1.00 
2.90 (1.07-7.90) 
Heart disease  
    No  
    Yes 
 
33 (83) 
7 (17) 
 
257 (89) 
32 (11) 
 
1.00 
1.70 (0.68-4.30) 
 
1.00 
1.10 (0.38-3.22) 
Anti-inflammatory factors  
Statins  
    No  
    Yes  
 
29 (73) 
11 (27) 
 
207 (73) 
78 (27) 
 
1.00 
0.97 (0.44-2.12) 
 
1.00 
0.68 (0.26-1.73) 
Anti-inflammatory3 
    No 
    Yes 
 
25 (63) 
15 (37) 
 
185 (64) 
104 (36) 
 
1.00 
1.04 (0.51-2.14) 
 
1.00 
0.85 (0.37-1.97) 
 
1- Multivariable regression adjusted for age and sex  
2- Multivariable regression adjusted for age, sex, BMI, diabetes and statin use 
3- Regular use of either statins, aspirin or NSAIDS 
For some variables, the summed total is less than the total number of patients because of missing values 
 
